Jacqueline E van Muijlwijk-Koezen
Overview
Explore the profile of Jacqueline E van Muijlwijk-Koezen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
55
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blaazer A, Singh A, Zara L, Boronat P, Bautista L, Irving S, et al.
ChemMedChem
. 2024 Aug;
19(22):e202400417.
PMID: 39193819
In search of new opportunities to develop Trypanosoma brucei phosphodiesterase B1 (TbrPDEB1) inhibitors that have selectivity over the off-target human PDE4 (hPDE4), different stages of a fragment-growing campaign were studied...
2.
Zara L, Moraca F, van Muijlwijk-Koezen J, Zarzycka B, Abel R, de Esch I
ACS Med Chem Lett
. 2022 Jun;
13(6):904-910.
PMID: 35707144
Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the parasite (.). A validated target for the treatment of HAT is the parasitic cyclic nucleotide phosphodiesterase B1 (TbrPDEB1)....
3.
FitzGerald E, Butko M, Boronat P, Cederfelt D, Abramsson M, Ludviksdottir H, et al.
RSC Adv
. 2022 Apr;
11(13):7527-7537.
PMID: 35423271
Biophysical screening of compound libraries for the identification of ligands that interact with a protein is efficient, but does typically not reveal if (or how) ligands may interfere with its...
4.
Zara L, Efrem N, van Muijlwijk-Koezen J, de Esch I, Zarzycka B
Drug Discov Today Technol
. 2021 Dec;
40:36-42.
PMID: 34916020
One of the remaining bottlenecks in fragment-based drug design (FBDD) is the initial exploration and optimization of the identified hit fragments. There is a growing interest in computational approaches that...
5.
Wijtmans M, Edink E, van Linden O, Zheng Y, Blaazer A, Siderius M, et al.
Drug Discov Today
. 2021 Feb;
26(6):1359-1368.
PMID: 33609778
A hybrid undergraduate practical course involving synthetic medicinal chemistry on neglected diseases bridges the gap between skills, techniques and scientific research, and exposes students to the nature of science.
6.
Smit M, van Muijlwijk-Koezen J
Mol Pharmacol
. 2019 Oct;
96(6):735-736.
PMID: 31624136
Chemokine receptors CXCR4 and atypical chemokine receptor 3 (ACKR3/CXCR7) are highly expressed in a range of tumors. Yet, their role in cancer progression is not well understood. This minireview series...
7.
Bach T, Jensen A, Petersen J, Sorensen T, Volpe S, Liu J, et al.
Eur J Med Chem
. 2015 Aug;
102:425-44.
PMID: 26301559
X-ray crystal structures of acetylcholine binding proteins (AChBPs) have revealed two different possible extensions to the classical ligand binding pocket known to accommodate various nicotinic agonists. One of the pockets...
8.
Thompson A, Verheij M, van Muijlwijk-Koezen J, Lummis S, Leurs R, de Esch I
ChemMedChem
. 2013 May;
8(6):946-55.
PMID: 23640722
Until recently, discriminating between homomeric 5-HT3A and heteromeric 5-HT3AB receptors was only possible with ligands that bind in the receptor pore. This study describes the first series of ligands that...
9.
de Graaf C, Vischer H, De Kloe G, Kooistra A, Nijmeijer S, Kuijer M, et al.
Drug Discov Today
. 2012 Dec;
18(7-8):323-30.
PMID: 23266367
Smaller stones with a wide variety of colors make a higher resolution mosaic. In much the same way, smaller chemical entities that are structurally diverse are better able to interrogate...
10.
Verheij M, Thompson A, van Muijlwijk-Koezen J, Lummis S, Leurs R, de Esch I
J Med Chem
. 2012 Sep;
55(20):8603-14.
PMID: 23006041
The 5-HT₃ receptor, a pentameric ligand-gated ion channel (pLGIC), is an important therapeutic target. During a recent fragment screen, 6-chloro-N-methyl-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine (1) was identified as a 5-HT₃ hit fragment. Here we...